| Dr J William Phillips Iii, MD | |
|
1655 Bernardin Ave Ste 220, Columbia, SC 29204-2044 | |
| (803) 409-7170 | |
| (803) 409-7175 |
| Full Name | Dr J William Phillips Iii |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 29 Years |
| Location | 1655 Bernardin Ave Ste 220, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114926797 | NPI | - | NPPES |
| 23595 | Other | SC | SC LICENSE |
| 235953 | Medicaid | SC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Health | Columbia, SC | Hospital |
| Kershawhealth | Camden, SC | Hospital |
| Musc Medical Center | Charleston, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Musc Community Physicians | 6507260668 | 698 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.
A medical student "operates" on a virtual patient. A surgeon sees an "augmented" vision of a patient with holograms and consults from other surgeons.
More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.
Doctors have discovered that combining images derived from positron emission tomography and computed tomography in the planning and delivery of radiation treatment for patients with head and neck cancer leads to more accurate delivery of the radiation dose and an increased chance for survival.
› Verified 8 days ago
| Entity Name | Prisma Health-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205889458 PECOS PAC ID: 6800708330 Enrollment ID: O20031110000506 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.
A medical student "operates" on a virtual patient. A surgeon sees an "augmented" vision of a patient with holograms and consults from other surgeons.
More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.
Doctors have discovered that combining images derived from positron emission tomography and computed tomography in the planning and delivery of radiation treatment for patients with head and neck cancer leads to more accurate delivery of the radiation dose and an increased chance for survival.
› Verified 8 days ago
| Entity Name | Providence Group Practices Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396192001 PECOS PAC ID: 2668768276 Enrollment ID: O20160908000669 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.
A medical student "operates" on a virtual patient. A surgeon sees an "augmented" vision of a patient with holograms and consults from other surgeons.
More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.
Doctors have discovered that combining images derived from positron emission tomography and computed tomography in the planning and delivery of radiation treatment for patients with head and neck cancer leads to more accurate delivery of the radiation dose and an increased chance for survival.
› Verified 8 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.
A medical student "operates" on a virtual patient. A surgeon sees an "augmented" vision of a patient with holograms and consults from other surgeons.
More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.
Doctors have discovered that combining images derived from positron emission tomography and computed tomography in the planning and delivery of radiation treatment for patients with head and neck cancer leads to more accurate delivery of the radiation dose and an increased chance for survival.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr J William Phillips Iii, MD Po Box 935722, Atlanta, GA 31193-5722 Ph: (843) 792-6200 | Dr J William Phillips Iii, MD 1655 Bernardin Ave Ste 220, Columbia, SC 29204-2044 Ph: (803) 409-7170 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.
A medical student "operates" on a virtual patient. A surgeon sees an "augmented" vision of a patient with holograms and consults from other surgeons.
More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.
Doctors have discovered that combining images derived from positron emission tomography and computed tomography in the planning and delivery of radiation treatment for patients with head and neck cancer leads to more accurate delivery of the radiation dose and an increased chance for survival.
› Verified 8 days ago
William Cole Andrew, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-8721 | |
Seetharamprasad Madala, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1801 Sunset Dr, Columbia, SC 29203 Phone: 803-434-4153 Fax: 803-434-4160 | |
Michael Martin, Internal Medicine Medicare: Medicare Enrolled Practice Location: 2 Medical Park Rd, Columbia, SC 29203 Phone: 803-434-6956 | |
Dr. Terry A Grainger, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Richland Medical Park Dr Ste 100, Columbia, SC 29203 Phone: 803-434-3800 Fax: 803-744-2759 | |
Dr. Adelero Olayinka Adebajo, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1520 Laurel St, Columbia, SC 29201 Phone: 803-799-8407 Fax: 803-252-9070 | |
Jeff Z Brooker Jr., MD, RETIRED Internal Medicine Medicare: Medicare Enrolled Practice Location: 1625 Bernardin Ave, Columbia, SC 29204 Phone: 803-251-8985 | |
Dr. Ronald L Collins, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1711 Saint Julian Pl, Columbia, SC 29204 Phone: 803-779-0911 Fax: 803-256-2480 |